David L. Veenstra, PharmD, PhD
Articles
October 14th 2021
Reimbursement for Genetic Variant Reinterpretation: Five Questions Payers Should Ask
David L. Veenstra, PharmD, PhD John W. Rowe, MD José A. Pagán, PhD H. Shelton Brown, PhD John E. Schneider, PhD Avni Gupta, BDS, MPH Sara M. Berger, MS, CGC Wendy K. Chung, MD, PhD Paul S. Appelbaum, MD
Periodic reinterpretation of genetic sequencing results presents a challenge for developing transparent and systematic coverage and reimbursement policies.
January 19th 2012
Systematic Review of Comparative Effectiveness Data for Oncology Orphan Drugs
Mindy M. Cheng, MS Scott D. Ramsey, MD, PhD Emily Beth Devine, PharmD, MBA, PhD Louis P. Garrison, PhD Brian W. Bresnahan, PhD David L. Veenstra, PharmD, PhD
This study critically assessed the published clinical and economic evidence supporting oncology orphan drugs marketed in the United States.
